Washington: A potential COVID-19 vaccine moved into human testing, a record pace for a virus scientists didn’t know existed a few months ago.
The first participant received the test vaccine on Monday. The trial began in the Seattle area, which became the epicentre of the US outbreak, with 42 of the 69 deaths in the nation.
Scientists at the National Institute of Allergy and Infectious Diseases developed the experimental vaccine in collaboration with biotechnology company Moderna Inc.
“Finding a safe and effective vaccine to prevent infection with SARS-CoV-2 is an urgent public health priority,” NIAID Director Anthony Fauci, said in a statement. “This Phase 1 study, launched in record speed, is an important first step toward achieving that goal.”